Total revenues increased 17% year-over-year; up 29%
excluding MRI asset sale

Conference Call today at 4:30 p.m. ET

NASHUA, N.H. (November 8, 2017) – iCAD, Inc. (NASDAQ: ICAD),
an industry-leading provider of advanced image analysis, workflow solutions and
radiation therapy for the early identification and treatment of cancer, today
reported financial results for the three and nine months ended September 30,

View Webcast

Full Results